Impact Biomedical Inc. Announces Executive and Director Changes

Ticker: IBO · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1834105

Impact Biomedical Inc. 8-K Filing Summary
FieldDetail
CompanyImpact Biomedical Inc. (IBO)
Form Type8-K
Filed DateMar 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, corporate-governance

TL;DR

Impact Biomedical Inc. is shuffling its execs and board; watch for new strategy.

AI Summary

Impact Biomedical Inc. announced on March 11, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers. The filing also covers the appointment of certain officers.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in key personnel and executive compensation can introduce uncertainty and potential strategic shifts, warranting closer investor scrutiny.

Key Players & Entities

  • IMPACT BIOMEDICAL INC. (company) — Registrant
  • Nevada (jurisdiction) — State of incorporation
  • 001-42212 (company_id) — SEC File Number
  • 85-3926944 (company_id) — IRS Employer Identification No.
  • 1400 Broadfield Blvd., Suite 130 Houston, TX 77084 (address) — Principal executive offices
  • (585) 325-3610 (phone_number) — Registrant's telephone number

FAQ

What specific roles were affected by the departures and appointments?

The filing indicates the departure of certain officers and directors, and the election of new directors, along with the appointment of certain officers. Specific names and titles are not detailed in the provided excerpt.

When did these changes become effective?

The date of the earliest event reported is March 11, 2025.

What is the primary business of Impact Biomedical Inc.?

Impact Biomedical Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Where is Impact Biomedical Inc. headquartered?

The company's principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, TX 77084.

What type of filing is this and what does it generally cover?

This is a Form 8-K, a Current Report, filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting significant corporate events such as the departure/election of directors and officers, and compensatory arrangements.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding IMPACT BIOMEDICAL INC. (IBO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.